Net margin is calculated as Net Income divided by its Revenue. Lonza Group's Net Income for the
six
months ended in Dec. 2025 was CHF-701 Mil. Lonza Group's Revenue for the
six
months ended in Dec. 2025 was CHF2,955 Mil. Therefore, Lonza Group's net margin for the quarter that ended in Dec. 2025 was -23.72%.
The historical rank and industry rank for Lonza Group's Net Margin % or its related term are showing as below:
XSWX:LONN'
s Net Margin % Range Over the Past 10 Years
Min: -4.21 Med: 13.47 Max: 54.43
Current: -4.21
XSWX:LONN's Net Margin % is ranked worse than 52.45% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs XSWX:LONN: -4.21
Lonza Group (XSWX:LONN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Lonza Group Net Margin % Related Terms
Lonza Group Net Margin % Historical Data
* Premium members only.
The historical data trend for Lonza Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:LONN vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Lonza Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where Lonza Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group (XSWX:LONN) has a Net Margin % of -23.72% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Lonza Group and its competitors. According to the industry distribution chart, Lonza Group ranks #107 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 52.5%.
Is Lonza Group's Net Margin % too high?
Lonza Group's current Net Margin % is -23.72%. Based on the distribution chart, Lonza Group ranks #107 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Lonza Group has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #107 out of 204 companies for Net Margin %. This places Lonza Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Lonza Group and its competitors. Lonza Group's current Net Margin % is -23.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (XSWX:LONN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF592.67, compared to a current price of CHF528.40 — trading 10.8% below its estimated fair value. The current Net Margin % is -23.72%. Lonza Group's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Lonza Group (XSWX:LONN), the current Net Margin % is -23.72% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (XSWX:LONN) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued.
The current stock price of CHF528.40 is trading 10.8% below its estimated GF Value™ of CHF592.67.
GuruFocus considers Lonza Group to be Modestly Undervalued.
Key valuation signals for XSWX:LONN:
Net Margin %: -23.72%
GF Value™: CHF592.67 vs. price of CHF528.40 (10.8% below fair value)
No single metric tells the full story. See the XSWX:LONN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
82GF Score
Get the complete analysis for XSWX:LONN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LONN has been successfully added to your 
